reference/2606786

Predicate	Object
contentType	Journal Article\|Review
endingPage	3883
issn	1177-8881
pageRange	3879-3883
publicationName	Drug Design, Development and Therapy
startingPage	3879
bibliographicCitation	Haugh IM, Preston AK, Kivelevitch DN, Menter AM. Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis. Drug Des Devel Ther. 2018;12():3879–83. PMID: 30518998; PMCID: PMC6237136.
creator	http://rdf.ncbi.nlm.nih.gov/pubchem/author/MD5_e23a6a008d77965de5c58fbc11b0b0eb http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-0247-9962 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0002-9314-0007 http://rdf.ncbi.nlm.nih.gov/pubchem/author/ORCID_0000-0001-7019-4830
date	201811
identifier	https://pubmed.ncbi.nlm.nih.gov/30518998 https://pubmed.ncbi.nlm.nih.gov/PMC6237136 https://doi.org/10.2147/dddt.s167149
isPartOf	https://portal.issn.org/resource/ISSN/1177-8881 http://rdf.ncbi.nlm.nih.gov/pubchem/journal/36020
language	English
source	https://pubmed.ncbi.nlm.nih.gov/ https://www.crossref.org/
title	Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
discusses	http://id.nlm.nih.gov/mesh/M0001357 http://id.nlm.nih.gov/mesh/M000631319 http://id.nlm.nih.gov/mesh/M0376076
discussesAsDerivedByTextMining	http://rdf.ncbi.nlm.nih.gov/pubchem/disease/DZID9007 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/MD5_7891ff73a5c685ddd0acd0d0450582b1

Predicate	Subject
isDiscussedBy	http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID3593 http://rdf.ncbi.nlm.nih.gov/pubchem/gene/GID51561 http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID404772212

Total number of triples: 29.